5-Methoxynaphthalene-1-carbaldehyde | 134594-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-Methoxynaphthalene-1-carbaldehyde
• 英文别名: 5-methoxy-1-naphthaldehyde；5-methoxy-[1]naphthaldehyde；5-Methoxy-[1]naphthaldehyd
• CAS: 134594-22-2
• 化学式: C₁₂H₁₀O₂
• 分子量: 186.21
• InChiKey: GZQNWVZECIRJHP-UHFFFAOYSA-N

物化性质

• 熔点：
  66 °C
• 沸点：
  340.2±15.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Methoxynaphthalene-1-carbaldehyde 在 乙硫醇钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以35%的产率得到5-羟基-1-萘甲醛
  参考文献：
  名称：

  In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor☆

  摘要：

  There is still a need for additional scaffolds to further explore tissue selectivity and improving efficacy of selective estrogen receptor modulators (SERMs). A series of hydroxyl substituted diphenylnaphthyl alkene ligands for the two estrogen receptors are described that arose from an initial de novo designed diphenylnaphthyl propylene ligand 1. All compounds gave K(j)s under 10 nM when assayed in the presence of ERalpha. Generally these compounds had very high affinity for both ER isotypes. Moving the hydroxyl group on naphthalene from the 6- to the 5-position of the alpha-naphthalene attached compounds (6b and 6e vs 6c and 6f) had little affect on ER binding nor did altering the position of the naphthalene attachment (alpha or beta) to the alkene moiety. In transfection assays none of the compounds displayed agonistic activity in the absence of E-2. In MCF-7 proliferation assays 6a-d, 6f and 12a-c successfully abrogated E-2 stimulation and resulted in greater than 50% inhibition at 1 muM, a level of efficacy similar to that obtained when the cells were treated with raloxifene. Our results show that this new class of SERMs are good candidates for further study as therapeutic agents for the treatment of breast cancer and osteoporosis. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.051
• 作为产物：
  描述：

  1-氰基-5-甲氧基萘 在 二异丁基氢化铝 、 水 、 溶剂黄146 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.17h， 生成 5-Methoxynaphthalene-1-carbaldehyde
  参考文献：
  名称：

  WO2008/142454

  摘要：

  公开号：

文献信息

• Regioselectivity in the reactions of methoxydehydrobenzenes with furans. Part 1. Reactions of 3-methoxydehydrobenzene and 3-(methoxycarbonyl)-dehydrobenzene with 2-substituted furans
  作者：Robin G. F. Giles、Melvyn V. Sargent、Hercules Sianipar

  DOI：10.1039/p19910001571

  日期：——

  obtained for the reaction of 3-methoxydehydrobenzene, generated from 2-amino-6-methoxybenzoic acid by aprotic diazotization, or from 2-bromo-3-methoxyphenyl toluene-p-sulphonate by treatment with butyllithium, and for the reaction of 3-(methoxycarbonyl)dehydrobenzene, generated from 2-amino-6-(methoxycarbonyl) benzoic acid by aprotic diazotization, with seven 2-substituted furans are recorded. These

  由2-氨基-6-甲氧基苯甲酸通过非质子重氮化而生成的3-甲氧基脱氢苯的反应，或由2-溴-3-甲氧基苯基甲苯-对磺酸酯经丁基锂的处理而生成的3-甲氧基脱氢苯的反应的环加合物的异构体比，以及记录了由2-氨基-6-（甲氧羰基）苯甲酸经质子重氮化而生成的3-（甲氧羰基）脱氢苯与七种2-取代的呋喃的反应。将根据异步，协调一致的双自由基反应途径来讨论这些结果。
• Ligands for Aldoketoreductases
  申请人：Yee Dominic J.

  公开号：US20100048604A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds useful for detecting the activity of human aldoketoreductase 1Cs, compounds useful for competitively inhibiting human aldoketoreductase 1Cs and compounds useful for treating human aldoketoreductase 1C-related cancers, as well as pharmaceutical compositions and methods of manufacture thereof.

  本发明涉及用于检测人类醛基酮还原酶1Cs活性的化合物，用于竞争性抑制人类醛基酮还原酶1Cs的化合物以及用于治疗人类醛基酮还原酶1C相关癌症的化合物，以及其制药组合物和制造方法。
• Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
  申请人：Prosidion Limited

  公开号：US08278442B2

  公开（公告）日：2012-10-02

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

  式(I)的化合物或其药学上可接受的盐，是阿片受体调节剂，例如μ-阿片受体拮抗剂，中性拮抗剂或逆激动剂，可用于治疗代谢性疾病，包括肥胖症。
• BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Bloxham Jason

  公开号：US20100173886A1

  公开（公告）日：2010-07-08

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

  化合物式(I)或其药学上可接受的盐，是阿片受体调节剂，例如μ-阿片受体拮抗剂，中性拮抗剂或倒向激动剂，并且可用于治疗代谢性疾病，包括肥胖症。
• One-Pot Green Synthesis of Cyclohepta[d]pyrimidine-2(5H)-thione Derivatives using Iron Titanate (FeTiO3, Ilmenite) Nanoparticles and Evaluation of their Antibacterial Activity
  作者：T. Rambabu、S. Paul Douglas、B. Venkateswara Rao

  DOI：10.14233/ajchem.2022.23702

  日期：——

  380-570 nm. Using these nanoparticles, cyclohepta[d]pyrimidine-2(5H)-thione derivatives (4a-e) were synthesized through one-pot approach with cycloheptanone (1), some substituted benzaldehyes (2a-e) and thiourea (3) as the precursors, which was performed under the guidelines of green chemistry. The progress of the reactions were monitored by TLC and the formed derivatives were characterized by using 1H NMR

  在超声处理下合成了钛酸铁纳米颗粒（FeTiO3-NPs、TiFe-0.5、TiFe-1.0、TiFe-2.0，分别具有固定和可变的 Fe 和 Ti 成分），并使用 XRD、FESEM-EDAX 和 UV-vis DRS 光谱技术进行表征。XRD分析清楚地表明了纳米颗粒的特征峰。形态显示出球形颗粒，并且在 EDAX 分析中，鉴定了制备的纳米颗粒中的各个元素（Fe、Ti、O）。类似地，纳米颗粒在 380-570 nm 之间的吸收最大值随着 Ti 含量的增加而增加。使用这些纳米粒子，以环庚酮 (1)、一些取代的苯甲醛 (2a-e) 和硫脲 (3) 作为原料，通过一锅法合成了环庚[d]嘧啶-2(5H)-硫酮衍生物 (4a-e)。前体，这是在绿色化学的指导下进行的。通过 TLC 监测反应进程，并使用 1 H NMR、FTIR 和质谱技术对形成的衍生物进行表征，并测定其熔点。纳米粒子是可磁分离的，并且以其回收形式，反应进行了